Education Program
Clinical Practice (Health Services and Quality), Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies
Hall B
(San Diego Convention Center)
Description:
The treatment of CLL has significantly advanced over the past decade with the introduction of novel targeted therapies. Inhibitors of Bruton’s tyrosine kinase (BTK) as well as BCL2 have supplanted chemoimmunotherapy in both frontline and relapsed therapy. However, while outcomes have improved in the current era, the disease is not cured, and questions still remain about optimal therapies for frontline and relapsed disease. This education session will focus on unanswered questions in CLL, and how current and upcoming research can answer these questions and continue to move the field forward.
Dr Stephan Stilgenbauer will discuss risk stratification in CLL and how genomic features influence treatment choice in the frontline setting. He will discuss the implications of genomic risk on outcomes with currently available therapies.
Dr Jennifer Woyach will discuss the evidence surrounding doublets and triplets in the frontline treatment of CLL. She will discuss scenarios in which doublets or triplets might be preferred over other standard options, and current and future trials that will help elucidate the use of these treatment for patients.
Dr Arnon Kater will discuss the role of immunotherapies in relapsed/refractory CLL. He will discuss the current evidence surrounding transplant, as well as newer paradigms including cellular therapies and bispecific antibodies.
Chair:
Jennifer A. Woyach, MD, The Ohio State University
Disclosures:
Woyach: Merck: Consultancy; Newave: Consultancy; Pharmacyclics: Consultancy, Research Funding; Loxo Lilly: Consultancy; Janssen: Research Funding; Genentech, Inc.: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy; AbbVie: Research Funding; Schrodinger: Research Funding; Morphosys: Research Funding.
The treatment of CLL has significantly advanced over the past decade with the introduction of novel targeted therapies. Inhibitors of Bruton’s tyrosine kinase (BTK) as well as BCL2 have supplanted chemoimmunotherapy in both frontline and relapsed therapy. However, while outcomes have improved in the current era, the disease is not cured, and questions still remain about optimal therapies for frontline and relapsed disease. This education session will focus on unanswered questions in CLL, and how current and upcoming research can answer these questions and continue to move the field forward.
Dr Stephan Stilgenbauer will discuss risk stratification in CLL and how genomic features influence treatment choice in the frontline setting. He will discuss the implications of genomic risk on outcomes with currently available therapies.
Dr Jennifer Woyach will discuss the evidence surrounding doublets and triplets in the frontline treatment of CLL. She will discuss scenarios in which doublets or triplets might be preferred over other standard options, and current and future trials that will help elucidate the use of these treatment for patients.
Dr Arnon Kater will discuss the role of immunotherapies in relapsed/refractory CLL. He will discuss the current evidence surrounding transplant, as well as newer paradigms including cellular therapies and bispecific antibodies.
Stephan Stilgenbauer, MD
Comprehensive Cancer Center Ulm, University of Ulm, Ulm, Germany
Jennifer A. Woyach, MD
Division of Hematology, The Ohio State University, Columbus, OH
Arnon P. Kater, MD, PhD
Hematology, Cancer Center Amsterdam, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands